Defective myogenic differentiation of human rhabdomyosarcoma cells is characterized by sialidase Neu2 loss of expression

Cell Biol Int. 2009 Sep;33(9):1020-5. doi: 10.1016/j.cellbi.2009.06.005. Epub 2009 Jun 12.

Abstract

Sialidase Neu2 is a glycohydrolytic enzyme whose tissue distribution has been detected principally in differentiated skeletal muscle. In this study we show that Neu2 expression is absent in different embryonal and alveolar human tumor rhabdomyosarcoma (RMS) cells, which are genetically committed myoblasts characterized by delayed differentiation. Forced myogenic differentiation of an embryonal RMS cell line, as obtained via pharmacological and genetic p38 activation or via follistatin overexpression, was characterized by Neu2 loss of expression despite the significant rise of different muscle-specific markers, suggesting therefore that the defective myogenic program of RMS cells is accompanied by Neu2 suppression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Caveolin 3 / metabolism
  • Cell Differentiation
  • Cell Line, Tumor
  • Follistatin / metabolism
  • Humans
  • MAP Kinase Kinase 6 / metabolism
  • Muscle Development*
  • Myoblasts, Skeletal / enzymology*
  • Myoblasts, Skeletal / pathology
  • Myosin Heavy Chains / metabolism
  • Neuraminidase / genetics
  • Neuraminidase / metabolism*
  • Rhabdomyosarcoma / enzymology*
  • Rhabdomyosarcoma / pathology
  • Tetradecanoylphorbol Acetate / pharmacology
  • Transfection

Substances

  • CAV3 protein, human
  • Caveolin 3
  • Follistatin
  • MAP Kinase Kinase 6
  • MAP2K6 protein, human
  • NEU2 protein, human
  • Neuraminidase
  • Myosin Heavy Chains
  • Tetradecanoylphorbol Acetate